Endothelin-B Receptor Activation in Astrocytes Regulates the Rate of Oligodendrocyte Regeneration during Remyelination  by Hammond, Timothy R. et al.
ReportEndothelin-B Receptor Activation in Astrocytes
Regulates the Rate of Oligodendrocyte Regeneration
during RemyelinationGraphical AbstractHighlightsd EDNRA and EDNRB are upregulated after demyelination in
reactive astrocytes
d Pharmacological inhibition of EDNRB, but not EDNRA,
accelerates remyelination
d EDNRB loss in astrocytes, but not in OPCs, accelerates
remyelination
d Endothelin indirectly inhibits OPC differentiation through
astrocytesHammond et al., 2015, Cell Reports 13, 2090–2097
December 15, 2015 ª2015 The Authors
http://dx.doi.org/10.1016/j.celrep.2015.11.002Authors
Timothy R. Hammond, Brian McEllin,
Paul D. Morton, Matthew Raymond,
Jeff Dupree, Vittorio Gallo
Correspondence
vgallo@cnmc.org
In Brief
Astrocyte-derived endothelin-1 (ET-1)
inhibits remyelination through unknown
mechanisms. Using pharmacological and
genetic approaches, Hammond et al.
demonstrate that ET-1 signals through
endothelin receptor-B in reactive
astrocytes, indirectly inhibiting
oligodendrocyte progenitor cell (OPC)
differentiation and remyelination.
Inhibiting this pathway could provide an
exciting therapeutic strategy to promote
remyelination in MS.
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Reactive astrogliosis is an essential and ubiquitous
response to CNS injury, but in some cases, aberrant
activation of astrocytes and their release of inhibi-
tory signaling molecules can impair endogenous
neural repair processes. Our lab previously identi-
fied a secreted intercellular signaling molecule,
called endothelin-1 (ET-1), which is expressed at
high levels by reactive astrocytes in multiple scle-
rosis (MS) lesions and limits repair by delaying
oligodendrocyte progenitor cell (OPC) maturation.
However, as ET receptors are widely expressed on
neural cells, the cell- and receptor-specific mecha-
nisms of OPC inhibition by ET-1 action remain
undefined. Using pharmacological approaches
and cell-specific endothelin receptor (EDNR) abla-
tion, we show that ET-1 acts selectively through
EDNRB on astrocytes—and not OPCs—to indirectly
inhibit remyelination. These results demonstrate
that targeting specific pathways in reactive astro-
cytes represents a promising therapeutic target
in diseases with extensive reactive astrogliosis,
including MS.
INTRODUCTION
Reactive astrogliosis is the cellular and biochemical transforma-
tion of astrocytes in response to brain injury, and it significantly
impacts—both positively and negatively—neural regeneration
(Sofroniew and Vinters, 2010; Williams et al., 2007). Reactive as-
trogliosis was once thought to be an all-or-nothing transforma-
tion, but emerging evidence suggests that reactive astrocytes
(RAs) are highly dynamic and tailor their transcriptional response
to the type of injury and the region in which it occurs (Zamanian
et al., 2012). This response includes production of growth fac-
tors, cytokines, and other intercellular signaling molecules that
influence the ability of progenitor cell populations to repair
damaged tissue. Therefore, it is essential to understand how
specific signals produced by RAs impact neural regeneration
so that we can develop targeted approaches to enhance the2090 Cell Reports 13, 2090–2097, December 15, 2015 ª2015 The Aubeneficial aspects of the astrocyte response while preventing
the deleterious ones.
Endothelin-1 (ET-1) is upregulated by astrocytes in a number
of brain pathologies, including stroke, traumatic brain injury,
Alzheimer’s disease, cancer, and multiple sclerosis (MS) (D’hae-
seleer et al., 2013; Hammond et al., 2014; Palmer et al., 2012;
Petrov et al., 2002; Schinelli, 2006; Stiles et al., 1997; Torbidoni
et al., 2005). While ET-1 has been well characterized for its role
as a secreted signaling peptide in the cardiovascular system,
its role in the normal and pathological brain is not well defined
(Rubanyi and Botelho, 1991). Both neurons and glia, including
astrocytes, express endothelin receptors (EDNRs), and ET-1
has been shown to promote reactive astrogliosis in vitro and
in vivo (Gadea et al., 2008; Schinelli, 2006). Interestingly, EDNR
inhibition improves recovery in several animal models of brain
injury (Guo et al., 2014a; Hammond et al., 2014; Moldes et al.,
2012), suggesting that ET-1 plays a deleterious role in the path-
ological lesion environment. However, given the widespread
expression of EDNRs, the mechanisms by which ET-1 signaling
impacts the regenerative response, including its effect on spe-
cific cellular targets, are not well understood.
MS is a disease characterized by oligodendrocyte (OL) death,
focal demyelinated CNS lesions, and extensive RA scar forma-
tion (Compston and Coles, 2008; Williams et al., 2007). In
response to demyelination, OL progenitor cells (OPCs) can
replace lost OLs by maturing into new myelin-producing cells
in a process called remyelination (Franklin and Ffrench-Con-
stant, 2008). However, stalled OPC differentiation is frequently
found in patients with progressive MS (Chang et al., 2002; Wols-
wijk, 1998), possibly due to the aberrant expression of signals
within the demyelinated lesions (Franklin and Ffrench-Constant,
2008). These signals could derive, at least in part, from perma-
nent astrocytic scars that are common in MS brain tissue.
ET-1 is highly upregulated in RAs in human chronic active MS
lesions and in experimentally induced demyelinated lesions in
mice (D’haeseleer et al., 2013; Hammond et al., 2014). We
recently showed that ET-1 contributes to stalled OPC differenti-
ation by promoting inhibitory astrocyte-OPC signaling (Ham-
mond et al., 2014). This led to delayed remyelination, an effect
that was reversed using EDNR antagonists during the repair
phase. Consistent with these findings, others demonstrated
that overexpression of ET-1 by astrocytes exacerbates experi-
mental autoimmune encephalomyelitis (EAE), a mouse modelthors
Figure 1. EDNR Expression Is Upregulated
in RAs following Demyelination
EDNRA and EDNRB expression was examined in
adult WT mice following LPC-induced demyelin-
ation of subcortical WM at 7 dpl.
(A and B) Images of brain sections stained with
anti-EDNRA and anti-EDNRB antibodies. In-
creases in EDNRA (A) and EDNRB (B) expression
were found in LPC lesions, as compared to saline
(NaCl)-injected contralateral control hemispheres.
(C) Quantification of EDNRA and EDNRB protein
expression by mean flourescent intensity within
the outlined regions in LPC and NaCl tissue is
shown (n = 4; *p < 0.05, unpaired t test; mean ±
SEM).
(D–F) Images show LPC lesions co-immunola-
beled with anti-EDNRA and anti-GFAP (RAs) (D),
anti-IBA1 (microglia) (E), and anti-Olig2 (OPCs/
OLs) (F).
(G–I) Images show LPC lesions co-immunolabeled
with anti-EDNRB and anti-GFAP (G), anti-IBA1 (H),
and anti-Olig2 (I).
Scale bars, 200 mm (A and B) and 50 mm (D–F and
G–I).of MS (Guo et al., 2014b). Despite these findings, it is still unclear
whether astrocyte-derived ET-1 solely acts by modulating the
astrocyte response to injury, including overactivation of inhibi-
tory astrocyte-OPC signaling pathways (as previously
described; Hammond et al., 2014), or whether astrocyte-derived
ET-1 also acts directly on OPCs, which also express EDNRs.
In our study, we used pharmacological approaches and cell-
specific genetic manipulation to understand the contribution of
indirect signaling through RAs to the mechanism of ET-1 action
following demyelinating injury inmice.We found that selective in-
hibition of EDNRB signaling, but not EDNRA, accelerated OL
regeneration and remyelination in demyelinated lesions. Condi-
tional deletion of Ednrb in RAs accelerated OPC differentiation,
OL regeneration, and increased myelin production, whereas
deletion of Ednrb in OPCs had no effect. Our results demonstrate
that RAs are a key intermediary that modulate OPC differentia-
tion in response to demyelinating injury, and that the response
of RAs, but not OPCs, to ET-1 can drastically inhibit the rate of
remyelination.
RESULTS
Our previous study demonstrated that the EDNRA/B pan-antag-
onist PD142,893 accelerated OPC differentiation, myelin sheath
production, and remyelination in mouse demyelinated lesions
(Hammond et al., 2014). Conditional ablation of ET-1 in RAs
also produced the same phenotype (Hammond et al., 2014),
indicating that activation of EDNRA and/or EDNRB by astro-
cyte-derived ET-1 limits OPC differentiation. EDNRA and
EDNRB are G protein-coupled receptors that trigger distinct
downstream signal transduction cascades through Gq/Gs and
Gq/Gi, respectively (Bigaud and Pelton, 1992; de Nucci et al.,
1988; Schinelli, 2006). While multiple ligands (ET-1, ET-2, and
ET-3) can bind to the EDNRA and EDNRB receptors, we found
in our previous study that ET-1 was the only isoform expressedCell Repin the subcortical white matter (WM) (Hammond et al., 2014).
To date, the expression patterns and cellular responses induced
by ET-1 on EDNRA and EDNRB have not been defined in the
context of demyelinating injury. Here we used a mouse model
of lysolecithin (LPC)-induced demyelination to address these
questions in vivo.
LPC was used to induce focal demyelinated lesions in one
hemisphere of the subcortical WM in mice. As a control, saline
(NaCl) was injected into the contralateral hemisphere. We first
examined the protein expression patterns of EDNRA and
EDNRB in wild-type (WT) LPC lesions at 7 days post-lesion
(dpl) (Figures 1A and 1B). Increases in EDNRA (Figures 1A and
1C) and EDNRB (Figures 1B and 1C) expression were found in
the LPC hemisphere (Figure 1). To determine which cells ex-
pressed each receptor, tissues were co-stained with antibodies
against GFAP (RAs), Olig2 (OPCs and OLs), and IBA1 (microglia)
(Figures 1D–1I). Significant EDNRA expression was found in
GFAP+ RAs, but not in microglia. Interestingly, EDNRA expres-
sion also was found in a subset of Olig2+ cells (Figure 1F). In
contrast, the vast majority of the EDNRB+ cells were RAs, with
little or no expression found in OPCs/OLs (Figures 1G–1I). One
of the few examples of EDNRB in OPCs/OLs is shown in Fig-
ure 1I. Low-level EDNRB expression alsowas observed inmicro-
glia (Figure 1H).
To test the function of each EDNR in LPC lesions, we infused
EDNRA antagonist BQ123 and EDNRB antagonist BQ788 into
WT demyelinated lesions using mini-osmotic pumps from 6 to
14 dpl (Figures 2A and 2B). For each condition, we examined
the rate of OPC differentiation into mature OLs, which are
marked by CC1. At 14 dpl, we found relatively few CC1+Olig2+
mature OLs in the saline-infused control mice and in the
BQ123-infused animals (Figures 2C, 2D, and 2F). However, in
the BQ788-infused animals, we found a large increase in the
number of mature OLs (Figures 2E and 2F). A significant increase
in the CC1+ to NG2+ cell ratio also was found in BQ788-infusedorts 13, 2090–2097, December 15, 2015 ª2015 The Authors 2091
Figure 2. EDNRB Inhibition, but Not EDNRA
Inhibition, Accelerates OPC Differentiation
during Remyelination
(A and B) Saline, EDNRA inhibitor BQ123, or
EDNRB inhibitor BQ788 was infused into demye-
linated LPC lesions (A) of adult WT mice from 6 to
14 dpl (B). Saline and BQ788 were infused from 6
to 8 dpl in adult TNR mice.
(C–E) Images of saline- (C), BQ123- (D), or BQ788-
infused (E) lesions co-immunolabeled with anti-
Olig2 and anti-CC1 antibodies at 14 dpl. White
arrowheads indicate CC1+Olig2+ cells.
(F) Significant increases in the number of
CC1+Olig2+ mature OLs were found in BQ788-
infused lesions, as compared to saline- and
BQ123-infused animals (n = 4–5; **p < 0.01,
ANOVA Bonferroni post hoc; mean ± SEM).
(G–I) Images show saline- (G), BQ123- (H), or
BQ788-infused (I) lesions co-immunolabeled with
anti-NG2 antibodies at 14 dpl.
(J) Significant increases in the CC1+ to NG2+ cell
ratio were found in BQ788-infused lesions, as
compared to saline- and BQ123-infused animals
(n = 4–5; *p < 0.05, ANOVA Bonferroni post hoc;
mean ± SEM).
(K and L) Images showTNRmouse LPC lesions at 8
dpl co-immunolabeledwith anti-GFP and anti-Olig2
antibodies insaline- (K)andBQ788-infused (L)mice.
(M) A significant decrease in the number of
EGFP+Olig2+ cells was found following BQ788
infusion (n = 3; *p < 0.05, unpaired t test; mean ±
SEM).
Scale bars, 40 mm (C–E and G–I) and 20 mm
(K and L). Also see Figure S1.lesions (Figures 2G–2J). No changes were found in total Olig2+
cell numbers (Figure S1A), indicating that changes in the
BQ788-infusedmice were due to precocious OPC differentiation
and not changes in the total number of OPCs/OLs.
We have shown previously that EDNRA/B antagonist
PD142,893 accelerates OPC differentiation by inhibiting Notch
activation in the transgenic Notch reporter (TNR) mouse
following demyelination (Hammond et al., 2014). Since BQ788
also increased rates of OPC differentiation (Figure 2F), we
infused BQ788 into the demyelinated lesions of TNR mice
to determine if EDNRB inhibition also led to a reduction in
Notch signaling. At 7 dpl, we observed a significant reduction
in EGFP+Olig2+ cells within the lesion (Figures 2K–2M), demon-
strating that inhibition of EDNRB activation is sufficient to reduce
Notch activation during remyelination.
Altogether, our results demonstrate that, despite elevated
expression of both receptors in demyelinated lesions (mostly in
RAs), only inhibition of the EDNRB accelerated OPC differentia-
tion. This could be due, in part, to reduced activation of Notch
signaling in OPCs.
Our previous studies showed that RAs regulate the rate of
remyelination through activation of EDNRs on RAs themselves
through an indirect pathway (Hammond et al., 2014). However,2092 Cell Reports 13, 2090–2097, December 15, 2015 ª2015 The Authorsseveral reports have demonstrated that
OPCs also express EDNRAs and
EDNRBs and respond to endothelinsdirectly (Gadea et al., 2009; Jung et al., 2011; Yuen et al.,
2013). Therefore, we sought to assess the relative contribution
of ET-1 signaling to OPCs and RAs individually by generating
cell-specific conditional knockouts of EDNRs. Based on phar-
macological results from our selective antagonist infusions, we
genetically ablated EDNRB on each cell type using conditional
knockout mice. Floxed Ednrb mice were bred to PdgfracreERT2
and hGfapcreERT2 mice to ablate EDNRB expression in OPCs
and RAs, respectively. Tamoxifen (Tam) was injected once a
day for 3 days prior to LPC-induced demyelination and brains
were analyzed at 14 dpl (Figure 3A).
By 14 dpl, EDNRB expression was noticeably reduced in
OPCs in Ednrbfl/fl;PdgfracreERT2 (Figure S2A) and Ednrbfl/fl;
hGfapcreERT2 (Figure S2B) mice treated with Tam, as com-
pared to Tam-treated Ednrb+/+Cre+ controls. At 14 dpl, we found
no change in the total number of mature OLs in Ednrbfl/fl;
Pdgfracre+ + Tam mice, as compared to Cre-negative and
vehicle-injected control littermates (Figures 3B–3D and 3L).
There was also no change in the total number of NG2+ OPCs
(Figures S3A–S3D), the CC1+ to NG2+ cell ratio (Figure S3E), or
the number of Olig2+ OPC/OLs (Figure S1B). The last finding
shows that the loss of EDNRB inOPCs had no effect on their abil-
ity to populate the demyelinated lesion. In addition, loss of
Figure 3. Selective EDNRB Ablation in As-
trocytes, but Not OPCs, Accelerates Re-
myelination
(A) Ednrbfl/fl;PdgfracreERT2 and Ednrbfl/fl;
hGfapcreERT2 mice were generated, and, prior to
LPC demyelination, Tam was injected once a day
from3 to1dpl (3 to 1 daysprior to LPC injection).
(B–D) Images of Ednrbfl/fl;Pdgfracreneg + Tam (B),
Ednrbfl/fl;Pdgfracre+ + Vehicle (C), and Ednrbfl/fl;
Pdgfracre+ + Tam (D) lesions at 14 dpl co-im-
munolabeled with anti-CC1 and anti-Olig2 anti-
bodies. White arrowheads indicate CC1+Olig2+
cells.
(E and F) EM images show LPC-injected lesions of
Ednrbfl/fl;Pdgfracre+ + Vehicle (E) and Ednrbfl/fl;
Pdgfracre+ + Tam (F) at 14 dpl.
(G–I) Images showEdnrbfl/fl;hGfapcreneg + Tam (G),
Ednrbfl/fl;hGfapcre+ + Vehicle (H), and Ednrbfl/fl;
hGfapcre+ + Tam (I) lesions at 14 dpl co-im-
munolabeled with anti-CC1 and anti-Olig2 anti-
bodies.
(J and K) EM images show LPC-injected lesions of
Ednrbfl/fl; hGfapcre+ + Vehicle (J) and Ednrbfl/fl;
hGfapcre+ + Tam (K) at 14 dpl.
(L) No changes were found in the total number of
CC1+Olig2+ cells between groups (n = 4–5; N.S.,
not significant, ANOVA Bonferroni post hoc; mean
± SEM).
(M) Significant increases in the number of
CC1+Olig2+ cells were found in Ednrbfl/fl;
hGfapcre+ + Tam lesions as compared to Ednrbfl/fl;
hGfapcreneg + Tam or Ednrbfl/fl;hGfapcre+ +
Vehicle mice (n = 4–5; *p < 0.05, ANOVA Bonfer-
roni post hoc; mean ± SEM).
(N and O) No changes in the number of the myelinated axons (N) or the g ratio (O) were found for either condition (n = 3–4; N.S., not significant, unpaired t test;
mean ± SEM).
(P and Q) Significant increases in the number of the myelinated axons (P) and decreased g ratio (Q) were found in Ednrbfl/fl;hGfapcreneg + Tam versus controls
(n = 3–4; *p < 0.05, unpaired t test; mean ± SEM).
Scale bars, 40 mm (B–D and G–I) and 2 mm (red scale bar; E, F, J, and K). Also see Figures S1–S4.EDNRB in OPCs had no effect on remyelination since there were
no changes in MBP immunostaining (compared to control, Fig-
ures S4A and S4B) or the number of myelinated axons and
myelin thickness (g ratio) as assayed by transmission electron
microscopy (EM) (Figures 3E, 3F, 3N, and 3O). To ensure that
EDNRB ablation in OPCs had no effect on the rate of OPC differ-
entiation, we characterized the terminal fate of Rosa-YFP+ OPCs
by co-staining with CC1 (Figures S3K–S3N). We found no differ-
ence in the total number of Rosa-YFP+CC1+ cells (Figure S3M) or
the percentage of Rosa-YFP+CC1+ cells (Figure S3N) between
Ednrbfl/fl;PdgfracreERT2 and Ednrb+/+;PdgfracreERT2 controls
at 14 dpl.
Since ablation of the EDNRB in OPCs had no effect on the rate
of OPC differentiation, we sought to determine if loss of the
EDNRB in RAs was sufficient to accelerate repair. Interestingly,
we found large increases in the number of CC1+Olig2+ OLs in
the lesions of Ednrbfl/fl;hGfapcre+ + Tam mice (Figures 3I and
3M), as compared to Cre-negative and vehicle-injected controls
(Figures 3G, 3H, and 3M). These increases were similar in magni-
tude to those seen following BQ788 infusion (Figure 2F). In-
creases in mature OLs were accompanied by a significant
decrease in the number of NG2+ OPCs (Figures S3F–S3I) and
an increase in the CC1+ to NG2+ ratio (Figure S3J). A small andCell Repinsignificant decrease was observed in the total number of
Olig2+ cells in the Ednrbfl/fl;hGfapcre+ + Tam mice (Figure S1C).
Consistent with the increase in CC1+Olig2+ population, Ednrbfl/fl;
hGfapcre+ + Tammice displayed increased remyelination. There
was a significant increase in the number ofmyelinated axons and
myelin thickness (decreased g ratio) in Ednrbfl/fl;hGfapcre+ +
Tam mice compared to Ednrbfl/fl;hGfapcre+ + vehicle controls
(Figures 3J, 3K, 3P, and 3Q), as well as increased MBP expres-
sion in the lesions (Figures S4A and S4B). There was no change
in the average axon diameter for any condition (Figure S4C).
BQ788 is a potent accelerator of OPC differentiation when
infused into demyelinated lesions (Figure 2F). Therefore, we
wanted to test whether infusion of BQ788 into lesions of
Ednrbfl/fl;PdgfracreERT2 mice could stimulate precocious OPC
differentiation by blocking astrocytic EDNRBs, or whether it
would provide any additional benefit in Ednrbfl/fl;hGfapcreERT2
mice. BQ788 was infused from 6 to 14 dpl following Tam admin-
istration before LPC demyelination (Figure 4A). In Ednrbfl/fl;
Pdgfracre+ + Tam mice, we found a significant increase in the
number of CC1+Olig2+ mature OLs following BQ788 infusion
compared to saline-infused controls (Figures 4B–4D), indicating
that inhibition of non-OPC EDNRBs in the lesion was sufficient to
accelerate OPC differentiation. On the other hand, infusion oforts 13, 2090–2097, December 15, 2015 ª2015 The Authors 2093
Figure 4. Astrocyte EDNRB Activation Pre-
dominantly Regulates OPC Differentiation
(A) Ednrbfl/fl;PdgfracreERT2+ and Ednrbfl/fl;
hGfapcreERT2+ mice were injected with Tam from
3 to 1 dpl. Saline or BQ788 was infused into
demyelinated lesions from 6 to 14 dpl.
(B and C) Images of Ednrbfl/fl;Pdgfracre+ saline- (B)
or BQ788-infused (C) lesions co-immunolabeled
with anti-Olig2 (OPC/OL) and anti-CC1 (OL) anti-
bodies at 14 dpl. White arrowheads indicate
CC1+Olig2+ cells.
(D) Significant increases in the number of
CC1+Olig2+ mature OLs were found in BQ788-
infused Ednrbfl/fl;Pdgfracre+ lesions, as compared
to saline-infused animals (n = 4–5; *p < 0.05,
unpaired t test; mean ± SEM).
(E and F) Images of Ednrbfl/fl;hGfapcre+ saline- (E)
or BQ788-infused (F) lesions co-immunolabeled
with anti-Olig2 and anti-CC1 antibodies at 14 dpl.
White arrowheads indicate CC1+Olig2+ cells.
(G) No difference in the number of CC1+Olig2+
matureOLswere found inBQ788-infusedEdnrbfl/fl;
hGfapcre+ lesions, as compared to saline-infused
animals (n = 4–5; N.S., not significant, unpaired
t test; mean ± SEM).
Scale bar, 40 mm for all images.BQ788 into Ednrbfl/fl;hGfapcre+ + Tam mice produced no addi-
tional increase in the number of CC1+Olig2+ cells compared to
saline-infused littermates (Figures 4E–4G).
Altogether, these results demonstrate that blocking ET
signaling through EDNRB in astrocytes alone is responsible for
modulating downstream effects on OPC differentiation and re-
myelination through our previously proposed indirect ET-1-
signaling pathway (Hammond et al., 2014), rather than through
direct activation of EDNRB on OPCs.
DISCUSSION
Prior to our study, the cell- and receptor-specific action(s) of
ET-1 following demyelinating injury were largely unexplored.
Here we found that ET-1 acts almost exclusively through
EDNRB, and not EDNRA, on astrocytes to inhibit remyelination.
RA-specific EDNRB ablation accelerated OPC differentiation
and remyelination, while activation of EDNRB signaling in
OPCs played little or no role in the differentiation or remyelination
process. Since it has been shown that EDNRB levels are2094 Cell Reports 13, 2090–2097, December 15, 2015 ª2015 The Authorselevated in active MS lesions (Yuen
et al., 2013), our results provide strong ev-
idence that selective pharmacological in-
hibitors of the EDNRB could be used to
promote remyelination and prevent OPC
differentiation failure in patients with MS.
Transcriptome analysis of the post-
natal mouse forebrain has revealed that
the Ednrb is enriched 7.6-fold in astro-
cytes versus neurons, OPCs, and OLs
(Cahoy et al., 2008). Consistent with
these findings, our data show that theenrichment is conserved in demyelinated lesions, where
EDNRB protein expression was predominantly confined to
RAs (Figure 1G). Higher levels of expression in RAs could
explain why ablating the receptor in astrocytes, but not
OPCs, had the greatest effect on OPC differentiation. Despite
these findings, OPC EDNRBs do exist at low levels and
in vitro studies have shown that direct ET-1 exposure can
impact OPC differentiation. However, these studies in cultured
OPCs have produced conflicting results; our lab found that
ET-1 exposure maintained OPCs in a premyelinating state (Ga-
dea et al., 2009), but another group found that ET-1 promoted
OPC maturation and myelin production (Jung et al., 2011).
Interestingly, ET-2 exposure also was found to promote differ-
entiation of cultured OPCs (Yuen et al., 2013). It is possible that
these discrepant results are due to low and variable levels of
EDNRBs in cultured OPCs. In the absence of other important
cell types like RAs, microglia, and the vasculature, it is hard
to interpret how these culture assays relate to the demyelinated
lesion environment, as in vivo we found no significant effects of
OPC EDNRB signaling on OPC differentiation.
Our findings beg the question of how, if at all, ET-1 directly im-
pacts OPCs following injury. One possibility is that ET-1 stimu-
lates a pro-migratory phenotype in OPCs, a result we previously
demonstrated in cultured OPCs and subventricular zone (SVZ)
explants (Gadea et al., 2009). However, here we found no major
differences in total OPC/OL cell numbers following drug infusion
or in the Ednrbfl/fl;PdgfracreERT2 mice. It is still possible that
ET-1 signaling could affect the contribution of SVZ versus paren-
chymal OPCs to the repair process or the timing of OPC recruit-
ment. Since significant OPC/OL EDNRA expression was found in
LPC lesions, this raises the question of whether EDNRA signaling
impacts OPC recruitment. Further studies will be needed to
address this and uncover the role of the EDNRA in the injured
brain.
In the brain, ET-1 promotes reactive astrogliosis, including
increased astrocyte proliferation and expression of the RA
marker GFAP (Gadea et al., 2008; Rogers et al., 2003). Interest-
ingly, the EDNRB antagonist BQ788 strongly reduces reactive
astrogliosis in models of stab-wound injury and demyelination
in rodents (Gadea et al., 2008; Koyama et al., 1999). In cultured
astrocytes, BQ788 blocked ET-1-induced increases in astrocyte
proliferation, but EDNRA inhibition had little or no effect (Gadea
et al., 2008). These findings, together with our results in this
study, suggest that activation of astrocytes through the EDNRB
and subsequent changes in the astrocyte activation state have
the greatest impact on regeneration following injury. Although
RAs are essential for normal recovery following brain injury, it ap-
pears that targeting specific aspects of their signaling response
to injury could be beneficial. This is especially true for disorders
where excessive or prolonged astrocyte activation, including
MS, could lead to altered activation of signaling pathways that
limit normal recovery.
All endothelin isoforms bind EDNRB with equally high affinity,
and EDNRB stimulation results in activation of JNK, p38MAPK,
ERK, and c-Jun pathways in RAs (Gadea et al., 2008; Schinelli
et al., 2001). Activation of these pathways can be blocked using
BQ788, but not by the EDNRA antagonist BQ123. ET-1 also in-
duces Jagged1 expression in astrocytes, which is inhibitory to
OPC differentiation (Hammond et al., 2014). Interestingly,
BQ788 also effectively blocked Notch activation in LPC lesions
(Figure 2M), suggesting that BQ788 also might reduce Jagged1
expression in RAs. While it is still unclear how EDNRB activation
leads to changes in Jagged1 transcription, it has been shown
that the activator protein-1 (AP-1) transcription factor binds the
promoter sequence of the Jagged1 gene (Johnston et al.,
2009). Furthermore, c-Jun, which is directly upregulated by
EDNRB activation, is a component of the heterotrimeric AP-1
complex (Horinouchi et al., 2013). This pathway will need to be
explored in greater detail, and it could have great importance
in other disorders where Notch activation contributes to
pathology.
Independent of Jagged-Notch signaling, it is likely that anal-
ysis of ET-1-treated astrocytes also would reveal other signals
that indirectly influence OPC development and remyelination.
Our analysis has shown that ET-1-treated astrocytes undergo
profound changes in vitro, including transcriptional changes in
hundreds of genes (T.R.H. and V.G., unpublished data). Because
RAs play such an important and influential role in the signalingCell Repmicroenvironment in demyelinated tissue (Brosnan and Raine,
2013; Williams et al., 2007), it is essential to understand how
these cells respond to signals like ET-1, which are released at
very high levels after several types of CNS injury both in rodents
and humans (Armstead and Kreipke, 2011; D’haeseleer et al.,
2013; Hammond et al., 2014; Palmer et al., 2012; Petrov et al.,
2002; Stiles et al., 1997; Torbidoni et al., 2005).
EXPERIMENTAL PROCEDURES
Animals
TNR (005854), floxed Ednrb (011080), and PdgfraCreERT2 (018280) mice were
purchased from the Jackson Laboratory. C57bl/6n mice were purchased from
Charles River Laboratories. The hGfapCreERT2 mice were obtained from
Dr. Flora Vaccarino at Yale University and were generated as previously
described (Ganat et al., 2006). Mice used for all experiments were 8–14 weeks
old unless otherwise specified. All mouse colonies were maintained in the an-
imal facility of Children’s National Medical Center, and all animal procedures
complied with the guidelines of the NIH and with the Children’s Research Insti-
tute Institutional Animal Care and Use Committee (IACUC) guidelines.
Tam Injections
Tam (Sigma, 90 mg/ml) was dissolved in 100% ethanol and then diluted in au-
toclaved sunflower oil (Sigma) to a final concentration of 10 mg/ml. Ednrbfl/fl;
hGfapcreERT2 and Ednrbfl/fl;PdgfracreERT2 mice were injected with 75 mg/kg
Tam once per day from3 to1 dpl. A vehicle solution of 10% ethanol in sun-
flower oil was injected into control animals.
LPC Injection
Mice were deeply anesthetized using 100 mg/kg ketamine and 10 mg/kg xyla-
zine. LPC (1% Lyso, 2 ml, EMD Chemicals) was injected unilaterally into the
external capsule of 8- to 14-week-old mice using a Hamilton syringe. On the
contralateral side, 2 ml 0.9%NaCl was injected for control purposes. Injections
were made using a stereotaxic apparatus at the following coordinates: 1.0 mm
anterior to bregma, 1.5 mm lateral, and 3.0mmdeep. The date of injection was
denoted as 0 dpl. Mice were then left for a period of 7, 8, or 14 dpl and subse-
quently perfused for immunohistochemical analysis.
Mini-Osmotic Pump Installation
Mice were deeply anesthetized using 100 mg/kg ketamine and 10 mg/kg xyla-
zine and unilateral LPC injections were performed in 8- to 14-week-old mice.
Mini-osmotic pumps (Durect) were assembled using a brain infusion kit
(0008851, Durect) with a 3-mm low-profile 30G stainless steel cannula and
1 in of polyethylene catheter tubing. Both the catheter tubing and mini-os-
motic pumps were preloaded with 0.9% saline, BQ123 (Tocris), or BQ788
(Tocris) and left overnight at 37C in 0.9% saline to initiate the pumping
process and ensure steady-state operation. For 6–8 and 6–14 dpl infusions,
we pre-loaded pumps (pump 107D) with 0.9% saline, 50 mM BQ123, or
50 mM BQ788. The approximate BQ123 and BQ788 delivery rates were
300 pmol/day. Mice were re-anesthetized and the pumps were installed into
a subcutaneous pocket at the base of the neck. The catheter tubing and can-
nula were led to the initial injection site, and the cannula was inserted into the
same skull perforation used for LPC injection, which was still visible. The can-
nula was attached to the skull using cyanoacrylate adhesive (0008670,
Durect). Brains were then used for immunohistochemical analysis.
Immunohistochemistry
Mice were anesthetized by isoflurane inhalation and perfused intracardially
with 13 PBS followed by 4% paraformaldehyde. Brains were removed and
postfixed, and immunocytochemical procedures and confocal microscopy
analysis (Zeiss LSM 510 NLO confocal microscope) were performed as previ-
ously described (Aguirre et al., 2007). Amplification using the Vectastain ABC
kit (Vector, PK-6100) followed by tyramide signal amplification (Life Technolo-
gies) were performed on EDNRA and EDNRB immunostainings according to
the manufacturers’ instructions. Blocking steps for endogenous avidin andorts 13, 2090–2097, December 15, 2015 ª2015 The Authors 2095
biotin also were performed using the Vector Avidin Biotin Blocking Kit (SP-
2001) according to the manufacturer’s instructions. Image acquisition and
analysis details and antibodies used are described in the Supplemental Exper-
imental Procedures.
EM
Mice were perfused in Millonig’s buffer containing 4% paraformaldehyde and
2.5% glutaraldehyde. A brain matrix was used to isolate the regions of interest,
which were postfixed in 1% osmium tetroxide, dehydrated, and embedded in
PolyBed resin. Thick (1-mm) and thin sections were stained with toluidine blue
and a combination of uranyl acetate and lead citrate, respectively. A minimum
of ten electron micrographs taken at 5,0003 were captured per mouse using
a JEOL JEM 1230 transmission electron microscope equipped with a Gatan
4K 3 4K Ultrascan digital camera.
Statistical Analysis
Specific numbers of animals or cultures are denoted in each figure legend. Sig-
nificance was calculated using GraphPad Prism software using unpaired
t tests for comparisons between two groups. For multi-group comparisons,
a one-way ANOVA with a Bonferroni post hoc analysis was used.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures
and four figures and can be found with this article online at http://dx.doi.org/
10.1016/j.celrep.2015.11.002.
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